-+ 0.00%
-+ 0.00%
-+ 0.00%

Connect Biopharma Q3 Net Loss Narrows 6% to $16.2 Million

PUBT·11/16/2026 21:10:04
Listen to the news
Connect Biopharma Q3 Net Loss Narrows 6% to $16.2 Million
  • Connect Biopharma’s third-quarter 2026 net loss narrowed 6% year over year to $16.2 million.
  • License and collaboration revenues rose to $700,000, primarily for cost reimbursements for development activities.
  • Research and development expense increased 15% to $12.8 million due to higher rademikibart-related development costs.
  • Cash, cash equivalents and short-term investments totaled $19.5 million at September 30, 2026.
  • FDA discussions on potential Phase 3 rademikibart programs are planned for December 2026 for asthma and first-quarter 2027 for COPD.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Connect Biopharma Holdings Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161605PRIMZONEFULLFEED9878636) on November 16, 2026, and is solely responsible for the information contained therein.